Nano-based delivery of RNAi in cancer therapy

RNA interference (RNAi), a newly developed method in which RNA molecules inhibit gene expression, has recently received considerable research attention. In the development of RNAi-based therapies, nanoparticles, which have distinctive size effects along with facile modification strategies and are ca...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cancer 2017-07, Vol.16 (1), p.134-134, Article 134
Main Authors: Xin, Yong, Huang, Min, Guo, Wen Wen, Huang, Qian, Zhang, Long Zhen, Jiang, Guan
Format: Article
Language:English
Subjects:
Apoptosis
Cancer
Cancer therapies
Cancer therapy
Care and treatment
Cloning
Current carriers
Cytoplasm
Disease
Drug Delivery Systems - methods
Drug development
Enzymes
Gene amplification
Gene expression
Gene therapy
Genetic Therapy - methods
Health aspects
Humans
Immune system
Metabolism
MicroRNAs
miRNA
Mutation
Nanocarriers
Nanoparticles
Nanoparticles - administration & dosage
Neoplasms - genetics
Neoplasms - therapy
Physiology
Polyamines
Review
RNA Interference - physiology
RNA polymerase
RNA-mediated interference
RNAi
siRNA
Vectors (Biology)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:RNA interference (RNAi), a newly developed method in which RNA molecules inhibit gene expression, has recently received considerable research attention. In the development of RNAi-based therapies, nanoparticles, which have distinctive size effects along with facile modification strategies and are capable of mediating effective RNAi with targeting potential, are attracting extensive interest. This review presents an overview of the mechanisms of RNAi molecules in gene therapy and the different nanoparticles used to deliver RNAi molecules; briefly describes the current uses of RNAi in cancer therapy along with the nano-based delivery of RNA molecules in previous studies; and highlights some other carriers that have been applied in clinical settings. Finally, we discuss the nano-based delivery of RNAi therapeutics in preclinical development, including the current status and limitations of anti-cancer treatment. With the growing number of RNAi therapeutics entering the clinical phase, various nanocarriers are expected to play important roles in the delivery of RNAi molecules for cancer therapeutics.
ISSN:1476-4598
1476-4598
DOI:10.1186/s12943-017-0683-y